The Insel Group and the Paul Scherrer Institute PSI are expanding their collaboration to provide faster and better coordinated access to proton therapy for patients with eye tumours. The two institutions have signed a new cooperation agreement, creating an integrated patient pathway that offers patients medically coordinated, high-precision treatment and improves the long-term quality of the care they receive.
The new contract ensures that patients with tumours in the eye region, especially uveal melanomas, are identified at an early stage by Bern University Hospital (Inselspital) and swiftly incorporated into the specialised treatment procedures available at PSI. Standardised procedures, regular interdisciplinary case discussions and coordinated aftercare ensure uninterrupted medical supervision – from the first suspicion to long-term monitoring. For patients, this means faster treatment, greater safety and reliably coordinated medical care.
“This integrated patient pathway will not only reduce the time until treatment but also ensure maximum safety for our patients through seamless collaboration between all the different specialists,” says Florian Heussen, Senior Consultant at the Department of Ophthalmology, Bern University Hospital.
Precise treatment with maximum protection of the eye
Proton therapy is one of the most advanced forms of radiotherapy. It allows tumours to be irradiated with sub-millimetre precision while at the same time protecting the surrounding healthy tissue as much as possible. This is a decisive advantage when treating the eye, which is extremely sensitive. “Our cooperation improves access to a treatment that can preserve the eye and the patient’s vision in complex cases”, says Damien Weber, Chief Physician and Head of the Center for Proton Therapy at PSI.
Pooling expertise for the direct benefit of patients
The agreement combines the strengths of two leading institutions: PSI as one of the internationally most renowned centres for proton therapy and Inselspital, whose University Comprehensive Cancer Center Inselspital (UCI) plays a central role in ocular oncology throughout Switzerland. The structured exchange and joint planning provide rapid, direct access to highly specialised care, setting a new quality standard for patients with eye tumours.
Contact
Prof. Dr. med. Damien Charles Weber
Head and Chief Physician of the Center for Proton Therapy
Paul Scherrer Institute PSI
+41 56 310 58 28
damien.weber@psi.ch
[English, French]
Further information
About PSI
The Paul Scherrer Institute PSI is the largest research institute for natural and engineering sciences in Switzerland. It is the central location of Switzerland’s large research facilities, available to both the scientific community and industry. Its research spans future technologies, energy and climate, health innovation and fundamentals of nature. The annual budget is CHF 450 million. PSI employs 2300 people; around a quarter of these are postdoctoral researchers, PhD students or apprentices. PSI is part of the ETH Domain, which also includes ETH Zurich and ETH Lausanne, as well as the other federal research institutes Empa, Eawag and WSL. (Current as of 06/2026)